Amendment to EXCLUSIVE LICENSE AgreementTo Exclusive License Agreement • September 11th, 2017 • Galena Biopharma, Inc. • Pharmaceutical preparations
Contract Type FiledSeptember 11th, 2017 Company IndustryThis Amendment to the Exclusive License Agreement, dated as of September 5, 2017 (the “Amendment”), by and between Mills Pharmaceuticals, LLC., a Delaware limited liability MPI (the “MPI”), and BioVascular, Inc., a Delaware MPI (the “BVI”), amends the Exclusive License Agreement, dated as of December 20, 2013, by and between the MPI and BVI (the “License Agreement”). Capitalized terms shall of the meaning set forth in the License Agreement unless otherwise set forth herein.